Skip to main content
| News

Bionter receives 3 million US dollars in investments

28.04.2022

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring to market its technology for counting sub-visible particles in liquid biologics this year.

Bionter, a company based in Riehen in the canton of Basel-Stadt, has raised its capital cover by a total of 3 million US dollars. The seed funding round for the Basel-based expert in testing sub-visible particles in liquid biologics was led by the venture capital company Dynamk Capital based in New York.

According to a press release, this funding accelerates the “already exceptional momentum” of Bionter’s first product. This comprehensive solution involves a particle counter with single-use consumables, maintenance, and training. It is suitable for use in the pharmaceuticals sector and is based on a new combination of light obscuration technology and smart automation.

On the market at the end of 2022

Bionter’s device aims to minimize the number of costly samples used to determine the particle count, increase efficiency, and reduce human interaction. According to the information provided, this improves the reliability of measurements, data integrity, and thus patient safety. Development for this patented technology has been concluded. It is expected to come to market at the end of 2022.

Bionter CEO Dr. Tobias Werk states: “This financing enables us to bring our first product to our customers while driving the development of new innovations. We are thrilled to have Dynamk Capital join our team, as they provide a wealth of experience growing life science tools companies and help position Bionter and help us to make our vision a reality.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.